|Bid||2.66 x 0|
|Ask||2.74 x 0|
|Day's Range||2.66 - 2.68|
|52 Week Range||2.63 - 6.06|
|PE Ratio (TTM)||-3.25|
|Earnings Date||May 12, 2017 - May 15, 2017|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||6.95|
LONDON, UK / ACCESSWIRE / September 21, 2017 / Pro-Trader Daily has lined up these stocks for our daily research reports coverage. Before the markets open, Pro-TD makes a brief technical snapshot of select ...
VANCOUVER, Sept. 12, 2017 /PRNewswire/ - Cardiome Pharma Corp. (NASDAQ: CRME / TSX: COM) today announced that it has entered into a distribution and license agreement with Basilea for its antibiotic Zevtera®/Mabelio®. Under the terms of the agreement, Basilea has granted Cardiome an exclusive license to commercialize ceftobiprole in 34 European countries and Israel. Cardiome will provide Basilea with an upfront payment and additional milestone payments based upon achievement of certain commercial and regulatory milestones.
Cardiome Announces Agreement with Basilea for Distribution of Zevtera®/Mabelio® (Ceftobiprole) in Europe and Israel